Sign In
Buy GLP
$48.63
+0.410 (+0.85%)
At Close: Jul 28, 2026
With a mean weight loss of 16.6%1, Wegovy® pill demonstrates best-in-class weight-loss efficacy and is the first oral GLP-1 treatment recommended by CHMP for weight management in the EU. CHMP recomme
Eli Lilly's New GLP-1 Drug Looks Like a Weight-Loss Powerhouse in New Trial
09:56am, Thursday, 21'st May 2026
Eli Lilly's investigational drug, retatrutide, delivered an average 80-week weight loss of 70 pounds at the highest dose.
Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide
09:00am, Thursday, 21'st May 2026
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada.
From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook
02:55pm, Wednesday, 20'th May 2026
Shares of Eli Lilly and Company NYSE: LLY, the world's most valuable pharmaceutical stock, started 2026 in a bad way. Near the end of April, LLY shares had fallen as much as 20%.
Novo Nordisk cautiously optimistic on key GLP-1 obesity study, says Deutsche Bank
10:46am, Wednesday, 20'th May 2026
Deutsche Bank has maintained its 'hold' rating on Novo Nordisk (NYSE:NVO) with a price target of DKK290 after hosting the Danish drugmaker's head of research and development, Martin Lange. Analyst Em
Novo Nordisk: 2 Reasons To Buy This GLP-1 Giant
05:49am, Wednesday, 20'th May 2026
I rated Novo Nordisk a Buy, trading at deep value after a 70% selloff and currently at ~10x trailing earnings. NVO's pipeline, including high-dose Wegovy, zenagamtide, and UBT251, positions it closer
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
03:31pm, Tuesday, 19'th May 2026
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
1Q26 MLP/Midstream Dividends: Growth Trend Continues
07:06am, Tuesday, 19'th May 2026
Key Takeaways: On a year-over-year basis, 96.0% of the Alerian Midstream Energy Index (AMNA) by weighting have grown their dividends. MLPs largely drove sequential growth in payouts for 1Q26, while mo
Are Investors Undervaluing Global Partners (GLP) Right Now?
10:40am, Monday, 18'th May 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Vancouver, Canada, May 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development
Hims & Hers Health: GLP-1 Drama Ending Signals Return To Growth
02:00pm, Sunday, 17'th May 2026
Hims & Hers Health has returned to growth mode after volatility from the GLP-1 transition, yet trades near multi-year lows. The online health platform guided up 2026 revenues to $3B, exceeding consens
As millions flock to GLP-1s, doctors warn of a rise in frailty caused by rapid muscle wasting
12:00pm, Sunday, 17'th May 2026
Losing muscle, as well as fat, is an unexpected downside of the popular drugs that isn't broadly discussed or immediately apparent.
Analysts say this restaurant chain has figured out how to feed everyone — GLP-1 users included
01:34pm, Thursday, 14'th May 2026
J.P. Morgan upgraded Cheesecake Factory's stock, as weight-loss drugs and cautious consumers make the restaurant industry more anxious.
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
11:20am, Thursday, 14'th May 2026
NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.
Global Partners (GLP) is an Incredible Growth Stock: 3 Reasons Why
01:46pm, Wednesday, 13'th May 2026
Global Partners (GLP) possesses solid growth attributes, which could help it handily outperform the market.
